Evolus, Inc.

Evolus, Inc. (NASDAQ: EOLS), headquartered in Newport Beach, California, is a high-growth medical aesthetics company that has disrupted the neurotoxin market through its Jeuveau brand. With $297.2 million in 2025 revenue (+12% YoY) and the 2025 launch of Evolysse fillers, Evolus is transitioning from a single-product challenger to a multi-product aesthetics platform.

1. Financial & Market Performance

Evolus generated $297.2 million in total 2025 revenue, representing 12% year-over-year growth. Jeuveau contributed $274.5 million, establishing the brand as the clear number-three US neurotoxin with approximately 10% market share. The company maintains a 70%+ gross margin through its asset-light manufacturing model and operates with a debt-free balance sheet — rare among growth-stage aesthetics companies. The 2025 launch of Evolysse HA fillers expanded Evolus' addressable market beyond the $3 billion US neurotoxin segment into the comparably sized dermal filler market. European market entry commenced in late 2025 with UK direct operations.

2. Manufacturing & Supply Chain

Evolus employs an asset-light, partnership-based supply chain. Jeuveau is manufactured by Daewoong Pharmaceutical (South Korea) under an exclusive supply agreement, while Evolysse fillers are sourced from Symatese (France). This capital-efficient model eliminates the burden of manufacturing infrastructure, enabling Evolus to concentrate resources on brand building and commercial execution. The company maintains strategic safety stock levels and dual-source qualification programs to ensure supply continuity. Quality oversight is managed through robust supplier auditing and lot-release testing protocols.

3. Key Developments & Strategic Outlook

Evolus' 2026 growth strategy centers on three pillars: deepening Jeuveau's US market penetration (with substantial room for expansion from the current ~10% share), scaling Evolysse distribution across US aesthetic practices, and executing the European expansion plan. The company's digital-first commercial engine — leveraging social media, KOL partnerships, and DTC marketing — has proven effective at millennial patient acquisition. Evolus is also developing next-generation products with Daewoong, including potential long-duration toxin formulations. While competition from Allergan and Galderma remains intense, Evolus' focused strategy, differentiated brand positioning, and capital efficiency position it as the most credible emerging competitor in the global neurotoxin market.